Shattuck Labs (STTK) Competitors $0.75 -0.01 (-1.52%) As of 08/1/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock STTK vs. CCCC, ACOG, ENTA, MOLN, GLSI, CTOR, NKTX, KRRO, CTNM, and IMRXShould you be buying Shattuck Labs stock or one of its competitors? The main competitors of Shattuck Labs include C4 Therapeutics (CCCC), Alpha Cognition (ACOG), Enanta Pharmaceuticals (ENTA), Molecular Partners (MOLN), Greenwich LifeSciences (GLSI), Citius Oncology (CTOR), Nkarta (NKTX), Korro Bio (KRRO), Contineum Therapeutics (CTNM), and Immuneering (IMRX). These companies are all part of the "pharmaceutical products" industry. Shattuck Labs vs. Its Competitors C4 Therapeutics Alpha Cognition Enanta Pharmaceuticals Molecular Partners Greenwich LifeSciences Citius Oncology Nkarta Korro Bio Contineum Therapeutics Immuneering Shattuck Labs (NASDAQ:STTK) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership. Is STTK or CCCC more profitable? Shattuck Labs has a net margin of 0.00% compared to C4 Therapeutics' net margin of -259.60%. C4 Therapeutics' return on equity of -45.86% beat Shattuck Labs' return on equity.Company Net Margins Return on Equity Return on Assets Shattuck LabsN/A -79.69% -69.13% C4 Therapeutics -259.60%-45.86%-28.96% Which has more risk & volatility, STTK or CCCC? Shattuck Labs has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 2.97, meaning that its share price is 197% more volatile than the S&P 500. Do insiders & institutionals hold more shares of STTK or CCCC? 58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 12.0% of Shattuck Labs shares are owned by insiders. Comparatively, 8.7% of C4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable earnings and valuation, STTK or CCCC? Shattuck Labs has higher earnings, but lower revenue than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioShattuck Labs$5.72M6.13-$75.41M-$1.39-0.53C4 Therapeutics$35.58M4.23-$105.32M-$1.47-1.44 Does the media prefer STTK or CCCC? In the previous week, Shattuck Labs and Shattuck Labs both had 1 articles in the media. Shattuck Labs' average media sentiment score of 0.00 equaled C4 Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral C4 Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend STTK or CCCC? Shattuck Labs currently has a consensus price target of $7.50, suggesting a potential upside of 924.59%. C4 Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 466.04%. Given Shattuck Labs' stronger consensus rating and higher probable upside, analysts plainly believe Shattuck Labs is more favorable than C4 Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shattuck Labs 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.83C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryShattuck Labs beats C4 Therapeutics on 9 of the 15 factors compared between the two stocks. Get Shattuck Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for STTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STTK vs. The Competition Export to ExcelMetricShattuck LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.48M$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-0.5317.6228.7823.81Price / Sales6.13179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book0.448.508.275.54Net Income-$75.41M-$55.06M$3.25B$259.28M7 Day Performance-13.50%-3.99%-3.70%-4.64%1 Month Performance-13.58%9.58%4.34%4.41%1 Year Performance-79.95%6.70%25.90%17.95% Shattuck Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STTKShattuck Labs2.9993 of 5 stars$0.73-3.9%$7.50+924.6%-80.6%$36.48M$5.72M-0.53100News CoverageUpcoming EarningsCCCCC4 Therapeutics2.3831 of 5 stars$2.18-3.5%$12.00+450.5%-68.3%$160.48M$35.58M-1.48150News CoveragePositive NewsACOGAlpha Cognition1.2242 of 5 stars$9.73-2.4%$20.00+105.5%N/A$159.72MN/A-8.11N/APositive NewsENTAEnanta Pharmaceuticals3.7048 of 5 stars$8.03+8.5%$18.50+130.4%-52.0%$158.19M$67.64M-1.77160News CoverageUpcoming EarningsAnalyst RevisionGap UpMOLNMolecular Partners2.172 of 5 stars$3.88+0.3%$12.00+209.3%-55.9%$156.19M$5.65M-2.02180Gap DownGLSIGreenwich LifeSciences1.3263 of 5 stars$11.55-0.2%$39.00+237.7%-28.4%$154.67MN/A-9.173Positive NewsCTORCitius Oncology1.3467 of 5 stars$1.87-5.1%$3.00+60.4%N/A$154.39MN/A0.00N/ANKTXNkarta2.3218 of 5 stars$2.20+1.9%$14.33+551.5%-66.9%$153.27MN/A-1.46140News CoveragePositive NewsKRROKorro Bio1.3267 of 5 stars$15.61-2.5%$102.43+556.2%-68.2%$150.34M$2.27M-1.6570CTNMContineum Therapeutics2.5052 of 5 stars$5.51-4.5%$22.50+308.3%-69.4%$149.28M$50M-2.8031News CoveragePositive NewsIMRXImmuneering2.9265 of 5 stars$3.91-3.7%$13.25+238.9%+149.6%$146.10M$320K-1.9960Upcoming EarningsGap Down Related Companies and Tools Related Companies C4 Therapeutics Competitors Alpha Cognition Competitors Enanta Pharmaceuticals Competitors Molecular Partners Competitors Greenwich LifeSciences Competitors Citius Oncology Competitors Nkarta Competitors Korro Bio Competitors Contineum Therapeutics Competitors Immuneering Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STTK) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shattuck Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shattuck Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STTK Stock Alerts